IDG-backed Shenogen Pharma said to tap banks for $300m Hong Kong IPO

Shenogen Pharma Group, the Chinese cancer drug developer backed by IDG Capital, is interviewing banks for a Hong Kong initial public offering that could raise as much as $300 million, people with knowledge of the matter said.